Episode Breakdown
- 0:00 – Intro and guest introduction
- 2:21 – Why high-risk neuroblastoma remains so hard to cure
- 4:01 – State of immune-based therapies in neuroblastoma
- 6:53 – Where GD2-directed therapy should live in the treatment course
- 10:46 – Radioimmunotherapy and MIBG in relapsed neuroblastoma
- 13:05 – Kids’ resilience, myelosuppression, and sequencing of therapies
- 17:05 – Tumor heterogeneity, GPC2 biology, and antigen loss under CAR pressure
- 22:57 – Dual targeting, cell states, and the limits of single CAR constructs
- 27:31 – Toxicity, ICANS/CRS, and the open question of CARs in solid tumors
- 30:29 – What will actually matter in the next 5 years?
We're excited to introduce another episode of the ImmunoLogic video podcast, hosted by Joseph Fraietta, PhD, an assistant professor of microbiology and the director of the Fraietta Lab at the University of Pennsylvania. Fraietta is joined by cohost Janna Minehart, MD, a clinical fellow in oncology (Master of Science Translational Research Program) at the University of Pennsylvania. Our hope is that this show will serve as a critical forum for clinicians, translational researchers, and biotechnology professionals to explore the evolving landscape of immunotherapy. We're seeking to bridge cutting-edge research with practical applications and delve into how immune-based therapies transition from innovative discoveries to transformative patient care solutions.
In this episode, the cohosts speak with Kristopher R. Bosse, MD, an attending physician in the Division of Oncology at Children's Hospital of Philadelphia, about how immunotherapy is reshaping treatment for high-risk neuroblastoma. Bosse, Fraietta, and Minehart cover topics including why high-risk neuroblastoma remains so hard to cure; the state of immune-based therapies in neuroblastoma; the place of GD2-directed therapy in the treatment course; tumor heterogeneity, GPC2 biology, and antigen loss under chimeric antigen receptor (CAR) pressure; and more.
ImmunoLogic is tailored for an audience fluent in the language of medicine and biotechnology, offering data-driven insights while maintaining accessibility. This podcast is an essential resource for those driving the future of immunotherapy.
Interested in cohosting an episode or being a guest? Have feedback to share? If you'd like to get in touch to talk about the show, contact our editorial director, Matt Hoffman: [email protected].
